Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week Open-Label Pilot Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Skin-Predominant Dermatomyositis

NCT06433999 is registered in ClinicalTrials.gov with Priovant Therapeutics, Inc. as lead sponsor.

NCT NCT06433999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06433999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week Open-Label Pilot Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Skin-Predominant Dermatomyositis
Lead sponsor
Priovant Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 28, 2024
Completion date
February 28, 2025
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis, dermatomyositis, adult type